TAK-715 odiamide hydrate 04) and a P-sel IC50

04) and a P-sel IC50 of 39

MLN-9708 treatment increases the levels of pro-apoptotic proteins and down regulates the anti-apoptotic proteins that control MOMP

painful menstruation

InChi: InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3

TAK-715 odiamide hydrate 04) and a P-sel IC50TAK 715 is a potent p38 MAPK inhibitor. which displays potent inhibitory activity (inhibition of p38alpha, IC50 = 7. 1 nM; LPS stimulated release of TNF alpha from THP 1, IC50 = 48 nM; LPS induced TNF alpha production in mice, 87. 6% inhibition at 10 mg kg, po) and no inhibitory activity for major CYPs, including CYP3A4. TAK 715 was selected as a clinical candidate and is now under clinical investigation for the treatment of RA. Product information